A case of severe psoriaticerythroderma with COVID-19. COVID-19 caused by the SARS-CoV-2, became pandemic very quickly. Management of severe dermatologic disorders in patients who require systemic immunosuppressive treatment is a major concern in COVID-19 pandemic era. Here, we report a 45-year-old homeless addicted male with second flare of psoriaticerythroderma and positive PCR test for COVID
Infective endocarditis following tumor necrosis factor-α antagonist therapy for management of psoriaticerythroderma: a case report The introduction of biological agents, such as infliximab, which act against tumor necrosis factor-α was a major advance for the treatment of an increasing number of chronic diseases. Tumor necrosis factor-α antagonists represent a major therapeutic advance for the management of chronic inflammatory diseases, such as psoriasis. Previous studies have reported that the use of tumor necrosis factor-α antagonists increased the risk of opportunistic infections and reactivation of latent bacterial infections. Cardiac involvement, such as infective endocarditis, is very rare in the literature. A 77-year-old Asian man with a 10-year history of psoriaticerythroderma
Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriaticerythroderma: results from a 52-week, open-label study. A T-helper (Th) cell subset Th17 preferentially produces interleukin (IL)-17 and plays a pivotal role in the pathogenesis of psoriasis. However, the pathological roles of IL-17 cascades in generalized pustular psoriasis (GPP) and psoriaticerythroderma (PsE) have not been well established. To evaluate the efficacy and safety of brodalumab, a human immunoglobulin G2 monoclonal antibody against human IL-17-receptor A (IL-17RA), in Japanese patients with GPP and PsE. This was an open-label, multicentre, long-term phase III study in Japanese patients with rare and severe types of psoriasis. Patients received brodalumab 140 mg at day 1 and weeks 1
Photoletter to the editor: Psoriaticerythroderma associated with bullous pemphigoid: clinical appearance and histopathology Psoriasis and bullous pemphigoid represent two clinically well-characterized, chronic, inflammatory skin conditions. The concomitant occurrence of these two entities in a patient is rare. We report a 62-year-old male with personal history of psoriasis vulgaris who developed disseminated bullous pemphigoid associated with psoriaticerythroderma. Skin histopathology from a scaly plaque was consistent with the diagnosis of psoriasis and showed subepidermal blister with inflammatory infiltrate of eosinophils with some neutrophils.
treatment and managementComplicationsPrognosisErythroderma preventionSynonyms: psoriaticerythroderma, erythroderma psoriaticaWhat is erythroderma?[1]Erythroderma is an extreme and often refractory variant of psoriasis with high morbidity and increased mortality. Erythroderma refers to a generalised redness of the skin. It involves all, or nearly all (usually stated as at least 90%), of the skin's surface
with CIE, atopic dermatitis (AD), psoriaticerythroderma (PsE), or generalized drug eruption (DE), who visited Fukuoka University Hospital Dermatology Department from 2010 to 2015, were enrolled. Their clinical and laboratory data were extracted from the patient database. CIE was defined as erythroderma without any apparent cause and lasting more than 3 months. Twenty-three CIE, 82 AD, 39 psoriaticerythroderma, and 99 drug eruption cases were enrolled. The mean age of CIE patients was 74.7 ± 8.8, and the male : female ratio was 21 : 2. Laboratory data for CIE and AD were similar, but serum levels of thymus and activation-regulated chemokine (TARC), a T-helper (Th) 2 cytokine, in the CIE group were significantly more elevated than in the AD group. Conversely, serum immunoglobulin (Ig) E levels were
, erythroderma in three and generalized pustular psoriasis in one patient. Response to therapy was excellent (>75% decrease in PASI) in all but three patients with psoriaticerythroderma. The mean time to control the disease, i.e. 50% reduction in PASI was 4.2 weeks. Side effects were mild, observed in two children, which included pain abdomen and an increase in serum creatinine over baseline value. CYC
supportive care and the use of anti-inflammatory immunosuppressive and biologic agents. We describe a case of psoriaticerythroderma which was triggered by withdrawal from systemic steroids and successfully treated with apremilast and cyclosporine. Apremilast induced atrial fibrillation limited its continued use after the initial response period.
. Patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis or psoriaticerythroderma who showed loss of efficacy to standard-dose therapy received infliximab dose escalation (10 mg/kg every 8 weeks) from weeks 0 to 32. Loss of efficacy was defined as not maintaining 50% reduction in the Psoriasis Area and Severity Index (PASI 50) after achieving PASI 75. Efficacy and safety were evaluated up
infusion.Preexisting malnutrition may become more marked and require nutritional intervention in older patients.Traditionally, topical corticosteroids under moist occlusion and phototherapy have been used to manage psoriaticerythroderma. [55] Five biologic agents have been approved for the treatment of psoriasis in the United States: infliximab, adalimumab, etanercept, ustekinumab, [56] and secukinumab [57
infusion.Preexisting malnutrition may become more marked and require nutritional intervention in older patients.Traditionally, topical corticosteroids under moist occlusion and phototherapy have been used to manage psoriaticerythroderma. [55] Five biologic agents have been approved for the treatment of psoriasis in the United States: infliximab, adalimumab, etanercept, ustekinumab, [56] and secukinumab [57
A Phase 4 Clinical Study of Brodalumab This study [4827-005 (post market)] is designed to evaluate the safety and efficacy of long-term exposure to brodalumab in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic arthritis) who have completed Study 4827-003 (Study 003) and in subjects with pustular psoriasis (generalized) or psoriaticerythroderma who have completed the Study 4827-004
, 15 men and 13 women (median age 39.4 years) with psoriasis refractory to three or more systemic treatments were included. Twenty presented with plaque-type psoriasis [median Psoriasis Area and Severity Index (PASI) score 25.9; range 7.2-48], five with psoriaticerythroderma (median PASI score 54; range 48-72) and three with generalized pustular psoriasis (GPP). Psoriatic arthritis was present in 13
Dramatic improvement of psoriaticerythroderma after acute hepatitis: analysis of cytokine synthesis capability in peripheral blood T cells. We report a patient with psoriasis and hepatitis C virus infection who initially presented with psoriaticerythroderma and eventually showed complete clearance of psoriatic lesions following acute hepatitis induced by etretinate treatment. Cytokine synthesis
Serum immunoglobulins in psoriaticerythroderma. The cause of psoriaticerythroderma (PE) is still unknown. Elevation of serum IgE has been reported in erythroderma, and as serum hyper-IgE is Th2 cell dominated it is of interest to investigate the serum IgE level in PE. In this study, the level of immunoglobulins in the sera of PE patients was analysed by a retrospective case-control study using
Case Number 29: Hitting three with one strike: rapid improvement of psoriatic arthritis, psoriaticerythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade)
Systemic side-effects of three topical steroids in diseased skin. Two clinical trials were carried out in order to study adrenal suppression in 6 patients with psoriaticerythroderma and in 28 patients with psoriasis treated with topical glucocorticosteroids. Betamethasone-17-valerate (0.1%), betamethasone-17,21-dipropionate (0.05%) and budesonide (0.025%) ointments were studied in erythroderma